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ABSTRACT 
This thesis explores two pathologies thought to be related to drug resistance in epilepsy that may 
themselves be causally related: 1) overexpression of drug transporters in capillaries and 2) 
inflammation. With regard to the first hypothesis, overexpression of the ATP-binding cassette (ABC) 
transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood-brain 
barrier are thought to contribute to drug resistance in epilepsy. To measure ABC transporter activity in 
vivo, positron emission tomography (PET) imaging can be used, which requires a radiolabeled substrate 
and non-radiolabeled inhibitor. The second hypothesis suggests that inflammation increases P-gp 
expression and, conversely, that inhibiting inflammation decreases P-gp expression. Questions remain 
however, as to the interactions between ABC transporters and specific inflammatory proteins, as well 
as the cellular expression of the same inflammatory proteins in the human brain.  
In Paper I, we characterized the BCRP inhibitor Ko143 to determine if it was a candidate for use in 
PET imaging. P-gp activity has been measured using PET imaging with tracers such as [11C]N-
desmethyl-loperamide (a P-gp substrate) along with a P-gp inhibitor such as tariquidar, but a similar 
imaging paradigm has not yet been developed for BCRP. Therefore, we performed multiple in vitro 
assays to characterize Ko143 and to measure its interaction with P-gp, BCRP, and the multidrug 
resistance transporter 1 (MRP1). Data from the in vitro assays indicated that while Ko143 was a potent 
BCRP inhibitor (IC50 = 9.7 nM), at higher concentrations it was a substrate for P-gp (IC50 = 2.7 µM) 
and MRP1. 
In Paper II, because of reports questioning whether tariquidar is a P-gp inhibitor, we investigated 
tariquidar to determine the mechanism by which it interacts with P-gp. Using similar methods as 
outlined in Paper I, we found that tariquidar was a potent P-gp inhibitor at low concentrations (IC50 = 
100 nM), but at higher micromolar concentrations it was a substrate and competitive inhibitor of BCRP. 
In Paper III, we sought to determine whether a relationship exists between ABC transporter expression 
and expression of the inflammatory enzymes cyclooxygenase (COX)-1 and -2, as well as the 
inflammation biomarker, translocator protein 18 kDa (TSPO). We used multiplex immunofluorescence 
to measure the expression of P-gp and BCRP as well as COX-1, COX-2, and TSPO in brain tissue 
samples from people with drug-resistant epilepsy. These tissue samples were classified as either having 
mesial temporal sclerosis (MTS) or not (non-MTS), in which the non-MTS samples acted as control 
tissue for MTS samples. When investigating the relationship between ABC transporters and the 
inflammatory proteins, the only correlation we observed was between BCRP and TSPO, in which 
increased BCRP density correlated linearly with increased TSPO density (P = 0.0003, r = 0.72131). No 
significant differences were found in the expression of any protein measured between MTS and non-
MTS tissue samples. 
In Paper IV, we investigated the cellular expression of three inflammatory proteins COX-1, COX-2, 
and TSPO in brain tissue samples from people with drug-resistant epilepsy. To do so, we used multiplex 
immunofluorescence microscopy to measure the expression of these proteins in microglia, astrocytes, 
and neurons. We found that that COX-1 was predominately expressed in microglia, while COX-2 and 
TSPO were expressed in microglia and neurons.  
In summary, this thesis explored the mechanisms underlying drug resistance in epilepsy. We studied 
overexpression of ABC transporters and inflammation, two pathologies hypothesized to be involved in 
drug-resistant epilepsy that may themselves possibly be related. While Ko143 is specific for BCRP at 
nanomolar concentrations (similar to tariquidar for P-gp), its potential utility as a radiolabeled inhibitor 
was diminished by the fact that PET requires picomolar affinity—rather than the 9.7 nM we measured—
to measure the low density of BCRP in the brain. With regard to inflammation, we found that COX-1 
is primarily expressed in microglia, a trait that makes it, rather than COX-2, a better radioligand for 
studying neuroinflammation in patients with drug-resistant epilepsy, given that microglia produce the 
majority of pro-inflammatory cytokines in the brain. 
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1 INTRODUCTION 
1.1 ABC TRANSPORTERS 
Treating a disease is a difficult task given the number of factors that have to be considered to 
ensure the therapy is effective. Treatment is further complicated if resistance develops to the 
medication, reducing treatment efficacy and patient quality-of-life. One mechanism of 
resistance involves reduction in cellular or tissue accumulation of therapeutics by the 
adenosine triphosphate (ATP) binding cassette (ABC) transporters. ABC transporters are 
endogenous efflux pumps that serve to protect cells from xenobiotics, and are strategically 
positioned in many blood-tissue (or blood-tumor) barriers throughout the body [1]. 
Overexpression of these transporters reduces the amount of drug that can diffuse into the 
tissue, thus conferring resistance in diseases such as cancer, human immunodeficiency virus 
(HIV), and epilepsy [2, 3]. As a consequence of reduced drug penetration, higher doses of 
medication are needed to maintain therapeutic effects, which can subsequently increase the risk 
for toxicity [4].  
The blood-brain barrier (BBB) poses a particularly difficult drug delivery hurdle to overcome 
when treating neurological diseases. The non-fenestrated blood vessels (capillaries) that 
comprise the BBB prevent paracellular entry to the brain (Figure 1) [5]. To cross the BBB, 
molecules need to have a low molecular weight (< 400 Da) and be highly lipid soluble in 
order to diffuse across brain endothelial cells [6]. To facilitate passage of biologically 
essential hydrophilic molecules that do not fit these parameters, carrier-mediated influx 
pumps such as glucose transporter 1 and organic anion transporter 2 exist to transport glucose 
and organic ions, respectively [7, 8]. Most drug-like molecules with the molecular properties 
to passively diffuse across the membranes of endothelial cells are often effluxed back into 
the lumen by ABC transporters [9]. The human genome encodes 48 members of the ABC 
family, eight of which are transporters expressed in the BBB [10]. Of these, P-glycoprotein 
(P-gp) and breast cancer resistance protein (BCRP) are the two transporters most extensively 
studied (Figure 1). 
1.1.1 P-glycoprotein (P-gp) 
P-gp (also called ABCB1 or MDR1) is a 170 kDa glycoprotein encoded by the ABCB1 gene, 
and was first identified in colchicine-resistant Chinese hamster ovary cells [11, 12]. It is made 
up of two structurally identical regions, each containing a membrane-spanning region and a 
nucleotide-binding domain, which are joined by a linker [13]. Expression of P-gp is highest in 
tissues that have an excretory function such as the intestine, liver, and kidneys, as well as in 
tissues requiring extra protection such as the blood-placenta and BBB [14]. P-gp functions by 
recognizing substrates in the lipid membrane and utilizing an ATP to pump the molecule 
against its concentration gradient back into the lumen [15, 16]. Substrates of P-gp include a 
wide range of xenobiotics such as antiepileptic drugs (AEDs), immunosuppresors, HIV 
protease inhibitors, and analgesics [14]. P-gp can also recognize some endogenous compounds 
of varying size such as beta amyloid, steroids, lipids, and small cytokines [14, 17].  
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Figure 1. Representation of ATP binding cassette (ABC) transporters present in the blood-brain barrier (BBB). 
The BBB is comprised of endothelial cells with tight junctions to protect the brain from potentially harmful 
molecules in the blood. Molecules necessary for brain function, such as glucose, bypass the BBB via influx 
transporters, such as glucose transporter 1 (Glut1). P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), 
and multidrug resistance protein (MRP) are ABC transporters that are responsible for effluxing xenobiotics from 
the brain into the blood.  
 
1.1.2 Breast cancer resistance protein (BCRP) 
BCRP (also called ABCG2 or MXR) is encoded by the ABCG2 gene and was first discovered 
in a multidrug-resistant breast cancer cell line (which is how it got its name) [18]. Its structure 
differs from P-gp in that BCRP is a homodimer made up of two ‘half-transporters’. Each half 
is 72 kDa and contains a transmembrane domain and an ATP-binding domain that need to 
dimerize to form a functional transporter unit [19]. Despite the difference in structure, BCRP 
performs the same function as P-gp and recognizes many of the same substrates, although 
chemotherapeutics like mitoxantrone are thought to be specific BCRP substrates [20]. BCRP 
is generally co-expressed in the same blood-tissue barriers as P-gp, and is also highly expressed 
in the canonical ‘side-population’ of cancer stem cells (for review see [21]). Certain 
polymorphisms of BCRP result in reduced function or non-functional variants, and while the 
former has some impact on substrate recognition, the latter increases the risk of hyperuricemia 
and gout [22, 23]. 
1.1.3 Inhibitors of P-gp and BCRP 
The ability of P-gp and BCRP to recognize a wide array of substrates complicates drug delivery 
to the brain. Because of this, inhibitors have been developed to circumvent the efflux action of 
ABC transporters, initially with the intention of addressing transporter-mediated multidrug 
resistance in cancer. Three generations of P-gp inhibitors have been tested in vitro, in vivo, and  
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Figure 2. Chemical structures of a BCRP inhibitor (Ko143) and a P-gp inhibitor (tariquidar). 
 
in clinical trials, but while some of these inhibitors are quite effective in vitro, the clinical data 
has failed to mirror this success [24, 25]. Of the third-generation inhibitors, tariquidar is the 
most potent P-gp inhibitor (Figure 2) [26]. When tested in cancer clinical trials, tariquidar was 
found to be ineffective at improving response to chemotherapy, and displayed moderate 
toxicity, presumably from ‘on-target’ inhibitory effects on P-gp in the liver, kidney, and at 
other sites [27]. Despite the negative results, tariquidar is frequently used as a tool in vitro and 
in animal models to study the activity of P-gp. At higher concentrations, tariquidar is a substrate 
of BCRP, but is a specific P-gp inhibitor at nanomolar concentrations [28]. Several potent 
inhibitors for BCRP have been utilized in vitro and in animal studies, such as fumitremorgin C 
(which cannot be used in vivo due to neurotoxicity) and its non-toxic analogue Ko143 (Figure 
2), however to date none have been employed in a clinical trial [20, 29]. 
1.1.4 Imaging P-gp and BCRP 
Imaging ABC transporters with positron emission tomography (PET) is the only non-invasive 
way to measure the activity or density of transporters in humans in vivo. Knowing the 
pathological role ABC transporters play could benefit the development of drugs able to cross 
the BBB. In order to measure P-gp or BCRP activity with PET, a drug (substrate) that is 
recognized by P-gp or BRCP, and is amenable to radiolabeling, is required. At baseline, a 
substrate radiotracer will not be able to enter the brain due to its efflux by P-gp or BCRP (or 
both). This is why an inhibitor (not radiolabeled) is needed at pharmacologic doses to block 
the efflux action of P-gp or BCRP. Accumulation of the substrate radiotracer in the brain after 
inhibition can then be measured. However, developing a substrate radiotracer for a specific 
ABC transporter is a challenge given the overlapping ligand affinity between P-gp and BCRP, 
and is made even more complicated because of the stringent requirements for a suitable PET 
radiotracer [30, 31]. 
1.1.4.1 P-gp 
For P-gp, there are several successful radiotracers that can be used to measure both activity or 
density. Radiotracers for measuring P-gp activity include the single photon emission computed 
tomography tracer [99mTc]sestamibi, as well as the PET tracers [11C]verapamil and [11C]N-
desmethyl-loperamide ([11C]dLop) [32-34]. Although [99mTc]sestamibi has been used  
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Figure 3. Imaging ABC transporters in vivo. (A) PET images of [11C]N-desmethyl-loperamide (dLop), a P-gp 
substrate radiotracer, in monkey and human brains. At baseline (top) there is no brain signal, and inhibition of P-
gp with an inhibitor (bottom) is necessary for uptake of [11C]dLop into the brain. (B) Bioluminescent signal due 
to uptake of D-luciferin into the mouse brain before (top) and after administration of 10 mg/kg Ko143 (bottom). 
Because D-luciferin is a substrate of the ABC transporter BCRP, inhibition of BCRP with Ko143 is necessary for 
uptake of D-luciferin into the brain.  
 
in the clinic more than any other P-gp radiotracer (for tumor imaging), [99mTc]sestamibi is also 
a substrate of BCRP and two other ABC transporters, multidrug resistance protein (MRP)-1 
and -2 [35], making it a poor candidate to specifically measure P-gp activity at the BBB. At 
micromolar concentrations verapamil acts as an inhibitor of P-gp, but at the picomolar 
concentrations used in PET, it behaves as a substrate and can therefore be used to measure P-
gp activity [15]. [11C]dLop is considered a better radiotracer than [11C]verapamil because it has 
a stronger affinity for P-gp (as evident by lower baseline signal), and is trapped in lysosomes 
which boosts brain signal (Figure 3A) [33]. Non-radiolabeled tariquidar is often used as the P-
gp inhibitor during scans with [11C]verapamil or [11C]dLop, and has been administered in 
humans at a dose of 2-6 mg/kg (though these doses do not fully inhibit P-gp) (Figure 3A) [36].  
To measure P-gp density, radiolabeled inhibitors such as [11C]elacridar, [11C]tariquidar, and 
[11C]laniquidar have been explored [37]. As inhibitors, these radiotracers are not transported 
by P-gp like [11C]dLop, but instead bind directly to P-gp (though this has been considered 
controversial, and is addressed in this thesis) [31]. Although the density of P-gp is high within 
the capillary bed itself (40 nM), its concentration per cm3 of tissue (which PET measures) is 
quite low (estimated to be 1.3 nM) due to the relatively low percentage of endothelial cells 
within the whole brain. This low density in tissue as a whole would require a radioligand with 
picomolar affinity, which is not the case for the aforementioned radiotracers [31]. 
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1.1.4.2 BCRP 
There are currently no successful BCRP substrate radiotracers for use in PET. Attempts to label 
BCRP substrates have been reported but none have been implemented in humans [38]. 
Dantrolene, a muscle relaxant and a possible BCRP-specific substrate, was radiolabeled for 
imaging studies in rodents but no imaging results have been published thus far [39, 40]. 
Imaging studies were performed with [11C]befloxatone in rats, and while befloxatone is a 
BCRP substrate in vitro, its uptake in vivo was not affected by BCRP [41]. 
 In mice however, there are two methods to measure BCRP activity. The first involves 
measuring the uptake of [11C]tariquidar (a substrate of BCRP) in a P-gp knockout mouse before 
and after inhibition of BCRP with Ko143 [42]. By genetically knocking out P-gp, any change 
in uptake of [11C]tariquidar can be solely attributed to BCRP. The second method involves 
measuring bioluminescence in the brain of transgenic mice (Figure 3B) [43]. These mice 
express firefly luciferase (fLuc) in astrocytes behind the BBB, and when they are injected with 
the fLuc substrate D-luciferin, bioluminescence is produced in the brain. Because D-luciferin 
is a BCRP substrate, co-administration of Ko143, or another BCRP inhibitor, is required to 
elevate the bioluminescent signal (Figure 3B) [43]. Neither of these methods however, can be 
applied to humans, so the search for a suitable BCRP substrate radiotracer remains ongoing. 
1.2 EPILEPSY 
Drug resistance affects approximately 30 percent of all persons diagnosed with epilepsy. Drug-
resistant epilepsy is defined as “a failure of adequate trials of two (or more) tolerated… AED 
regimens… to achieve freedom from seizures” [44]. For patients with drug-resistant epilepsy, 
the most effective treatment is often the surgical resection of the epileptic focus [45]. Several 
hypotheses exist to explain why these patients are unresponsive to AEDs, the two most 
prevalent being the “target hypothesis” and the “transporter hypothesis” [44]. The target 
hypothesis states that the intended drug targets themselves have changed, so that the drug can 
no longer bind to its receptor and exert an effect. Although there has been some research that 
supports this notion, this does not explain why drug-resistant patients are non-responsive to 
drugs with different mechanisms of action [44]. 
1.2.1 The transporter hypothesis 
The transporter hypothesis proposes that ABC transporters are responsible for preventing entry 
of AEDs into the brain (Figure 4) [44]. The validity of this hypothesis relies on research 
showing an upregulation of ABC transporter expression or function in the brain capillaries of 
patients with drug-resistant epilepsy. Multiple groups have investigated the expression of P-gp 
in brain tissue samples from patients with drug-resistant epilepsy, and have found a consistent 
increase in expression when compared to control tissue. These studies were conducted using 
tissue samples from patients with some form of temporal lobe epilepsy [46-52], focal cortical 
dysplasia [51, 53, 54], tuberous sclerosis [55], or brain tumor [51, 54]. A potential caveat of 
these studies is the type of control tissue used as a comparison. Since it is impossible to obtain  
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Figure 4. Diagram of the transporter hypothesis of drug-resistant epilepsy. ABC transporters (yellow squares) are 
endogenously expressed in the healthy brain at normal levels (left panel), which permits passage of xenobiotics 
like antiepileptic drugs (AEDs, asterisks) into the brain. In drug-resistant epilepsy (center panel), ABC transporter 
expression is upregulated and therefore prevents passage of AEDs into the brain. To bypass the efflux mechanism 
of the ABC transporters, transporter-specific inhibitors (X’s) can be administered (right panel), allowing AEDs to 
enter the brain.  
 
surgically resected tissue from healthy people, these studies had to rely on postmortem samples, 
tissue obtained through other types of brain surgery, or commercially purchased cell cultures. 
A lack of available proper control tissue makes these findings difficult to interpret and less 
conclusive. It is not clear if ABC transporters are also overexpressed in healthy people, or in 
patients with drug-responsive epilepsy.  
For BCRP, there are mixed results as to whether expression is increased in drug-resistant 
epilepsy. No upregulation of BCRP was detected in samples with hippocampal sclerosis, focal 
cortical dysplasia, or dysembroplastic neuroepithelial tumor [56]. And while a second study 
also found no upregulation of BCRP in hippocampal sclerosis tissue samples, they did find an 
upregulation of BCRP in tissue from brain tumors associated with epilepsy pathologies [57]. 
In capillaries isolated from pediatric patients with drug-resistant epilepsy, BCRP expression 
decreased after the addition of glutamate, which is the opposite of what is expected given that 
P-gp expression increased using the same model [58].  
In addition to increased ABC transporter expression, in order for the transporter hypothesis to 
be upheld, ABC transporters need to recognize AEDs as substrates. In other words, if AEDs 
are not substrates of drug efflux transporters, then the overexpression of ABC transporters 
should have no impact on AED efficacy. There have been numerous studies conducted 
investigating whether ABC transporters recognize commonly used AEDs. For P-gp, there is in 
vitro and in vivo evidence that AEDs such as phenytoin and phenobarbital are weak substrates 
[59], while for BCRP the results are conflicting [60, 61]. Based on this, the P-gp inhibitor 
verapamil has been investigated as an adjuvant therapy for patients with drug-resistant 
epilepsy. While some studies reported a positive influence of verapamil in addition to AEDs 
[62-64], a double-blinded, placebo-controlled trial found the addition of verapamil to have only 
a mild benefit [65]. 
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1.2.2 Imaging P-gp activity in epilepsy 
P-gp radiotracers have been used in rodent seizure models as well as in humans to explore 
whether P-gp activity or density are increased in drug-resistant epilepsy. In a rat model of 
temporal lobe epilepsy, those animals deemed ‘non-responders’ (drug-resistant) showed a 
significant increase of [18F]MPPF (a P-gp substrate radiotracer) activity in the brain after 
tariquidar treatment as compared to the ‘responder’ group [66]. However in another study, only 
small changes were detected in the baseline uptake of [11C]verapamil in kainate seizure-
induced rats versus controls, in which inhibition via tariquidar increased brain uptake equally 
in both groups [67]. No difference in brain signal before and after tariquidar dosing was 
observed in electrode-implanted rats using [11C]quinidine (a P-gp inhibitor radiotracer) and 
[11C]laniquidar [68]. The first application of [11C]verapamil in patients with drug-resistant 
epilepsy showed no statistically significant differences in uptake between epileptogenic and 
nonepileptogenic brain regions [69]. However, a follow up study with a larger patient cohort 
did reveal decreased [11C]verapamil uptake in drug-resistant epileptics than in seizure free 
patients in certain temporal lobe regions. In addition, administration of tariquidar resulted in 
less uptake of [11C]verapamil in drug-resistant patients compared to healthy controls [70]. Both 
of these responses (i.e., decreased uptake of verapamil before and after tariquidar) are 
consistent with drug-resistance being associated with, and perhaps caused by, increased activity 
of P-gp. 
1.3 INFLAMMATION 
1.3.1 ABC transporters and inflammation 
A different approach to inhibiting ABC transporter efflux is to understand the pathways that 
regulate transporter expression. Understanding these mechanisms could reveal upstream 
targets that could be manipulated to decrease transporter activity or expression. One of these 
processes is thought to be inflammation [71]. Studies conducted within the past decade have 
found a strong connection between inflammation and P-gp expression. Increases in 
inflammatory markers have been measured in brain tissue from patients with epilepsy with an 
autoimmune or viral origin, but the involvement of inflammation in mesial temporal lobe 
epilepsy is unknown [72]. It is also unknown whether inflammation is merely a byproduct of 
seizure activity or a contributing factor to the progression of the disease [72]. Nonetheless, 
modulation of P-gp expression through pharmacologic manipulation of specific inflammatory 
markers is a possible method to increase drug delivery to the brain.  
The link between P-gp expression and inflammation was first studied in the intestine and the 
liver. There are mixed data regarding the expression of P-gp in models of intestinal 
inflammation. In tissue samples from patients with active ulcerative colitis [73, 74], Crohn’s 
disease, collagenous colitis, and diverticulitis patients [73], P-gp expression was 
downregulated compared to control tissue. In an induced inflammation model in rats, P-gp 
expression was decreased in the inflamed tissue [75, 76], but increased in the surrounding 
healthy tissue, suggesting a compensatory mechanism [75]. The same decrease in P-gp 
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expression was also observed in a lipopolysaccharide (LPS) model of inflammation in rats [77]. 
On the other hand, increases in P-gp expression were measured in human tissue samples of 
ulcerative colitis [78]. In biopsies from children with Crohn’s disease, P-gp mRNA levels were 
significantly higher than in control tissue [79]. Tissue from an experimental rat colitis model 
displayed a slight increase in P-gp activity [80]. Exposure of Caco-2 cells (a model of intestinal 
P-gp) to pro-inflammatory cytokines through direct addition or by co-culturing with 
macrophages increased P-gp mRNA expression [81]. In rats, indomethacin-induced small 
intestinal ulcerations and adjuvant-induced arthritis did not have any effect on mdr1a mRNA 
expression [82], and mdr1a/1b mRNA expression [83], respectively.   
For hepatic P-gp, there seems to be a consistent outcome of decreased expression during 
inflammation. In models of induced inflammation, P-gp expression decreased after 
administration of the LPS [84-88], turpentine [85, 87, 89], interleukin (IL)-6 [85, 89-92], IL-
1β [91, 92], tumor necrosis factor alpha (TNFα) [91], and in an adjuvant-induced model of 
arthritis [83]. In a follow up study however, IL-1β and TNFα were found to increase mdr1b 
mRNA [85]. Additionally, MDR1 mRNA expression was the same in tissue from patients with 
inflammation-induced icteric cholestasis as compared to controls [93]. This discrepancy in 
outcome for both intestinal and hepatic P-gp expression may be due to the model used. 
Fernandez and colleagues found that P-gp expression differs depending on what compound is 
used to induce inflammation, but nevertheless concluded that there is a general trend of 
decreased P-gp expression and function in the intestine and liver [94]. 
Similar to the liver and intestine, changes in P-gp expression at the BBB seem to be dependent 
in part on the model used to study inflammation. Increases in P-gp have been observed after 
exposure to lymphocytes [95], 6-hydroxydopamine [96], TNFα [97-101], IL-1β [99], 
endothelin 1 [97, 102], and diesel exhaust particles [103]. Conversely, decreases have been 
observed after exposure to LPS [84, 88, 104], IL-6 [98, 99], HIV-1 viral envelope glycoprotein 
[99], and IL-1β [100]. Bauer and colleagues found that the time-course for their experiments 
dictated the type of P-gp modulation, reinforcing the importance of study design. In isolated 
rat brain capillaries, initial administration of either TNFα or endothelin 1 acutely decreased P-
gp expression, which then rebounded and doubled that of control capillaries after six hours 
[97]. For BCRP, TNFα, IL-1β [100], and LPS injection [104] decreased expression while 
endothelin 1 increased expression [102]. 
1.3.2 Translocator protein 
Originally called the peripheral benzodiazepine receptor, translocator protein 18 kDa (TSPO) 
is a transporter located in the outer mitochondrial membrane. TSPO is thought to transport 
cholesterol to an enzyme which converts it to pregnenolone, a precursor for steroids and 
neurosteroids [105]. TSPO is highly expressed in microglia and astrocytes; increases of TSPO 
correlate to increases in microglia activity, therefore making TSPO a biomarker of 
inflammation [106]. Increases in TSPO expression is also observed in diseases such as 
epilepsy, Alzheimer’s disease, and Parkinson’s disease [105, 107, 108].  
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To measure TSPO activity in the brain, the radiotracers [11C]PK11195, [11C]PBR28, and 
[11C]DPA-713 have been developed. In rat models of temporal lobe epilepsy, increases in 
[11C]DPA-713 signal correlated with symptom severity [109], and with brain areas known to 
be affected by kainic acid [110]. One study measuring neuroinflammation in a rat model of 
drug-resistant epilepsy found increased TSPO signal (using [11C]PK11195) in rats considered 
to be ‘non-responders’ to AEDs compared to ‘responders’ and non-epileptic controls. The 
authors could not definitively conclude that this was related to drug resistance however, 
because the ‘non-responders’ also exhibited higher seizure severity [111]. In humans, there 
was an increase in [11C]PBR28 and [11C]DPA-713 signal ipsilateral to the seizure focus 
compared to the contralateral side, as well as compared to age-matched healthy controls [106, 
112]. 
1.3.3 Cyclooxygenase 
Cyclooxygenases (COX) are enzymes involved in the inflammatory cascade, and act by 
converting arachidonic acid into prostanoids (Figure 5) [113]. The two isoforms COX-1 and 
COX-2 are thought to hold opposing roles during an inflammatory response. COX-1 is 
understood as being responsible for homeostatic prostaglandin synthesis, while COX-2 is 
thought to be a pro-inflammatory marker, in which expression is acutely increased after an 
inflammatory event [114]. However recent studies have challenged these notions by showing 
that COX-1 also has a pro-inflammatory role, and that COX-2 can have anti-inflammatory 
functions [115]. COX-1 and COX-2 also differ in cellular expression in the brain. Both are 
expressed in microglia and endothelial cells, but COX-1 is also found in macrophages, while 
COX-2 is also expressed in neurons [114, 115].  
When expression of COX-2 was shown to be upregulated in tumors, studies began to 
investigate possible links between COX-2 and ABC transporters. In breast [116] and ovarian 
[117, 118] cancer tissue samples, increases in COX-2 expression correlated with increases in  
 
 
Figure 5. Flow chart of the cyclooxygenase (COX) cascade. Both COX-1 and COX-2 work by converting 
arachidonic acid into prostaglandin G2 (PGG2) and then into prostaglandin H2 (PGH2). PGH2 is then converted 
into one of three types of prostanoids: prostacyclin, prostaglandin, or thromboxane.  
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P-gp expression. P-gp expression increased after transfecting rat mesangial cells with COX-2 
[119], after the addition of prostaglandin E2 to primary rat hepatocyte cultures [120], and by 
exposing caco-2 cells to trinitrobeneze sulfonic acid [121]. The latter was also reproduced in 
vivo [121]. Cell lines expressing high levels of P-gp also express COX-2 [122-124]. In each 
study, inhibition of COX-2 prevented the upregulation of P-gp [119-124]. 
The same relationship between COX-2 and P-gp has been observed in BBB endothelial cells 
[125, 126]. Exposing isolated rat, mouse, or human (from surgical resection of the epileptic 
focus) brain capillaries to glutamate increased P-gp expression, which could be blocked with a 
selective COX-2 inhibitor [127-129]. Higher P-gp expression was attenuated in a rat seizure 
model after a general COX inhibitor [128] and after a specific COX-2 inhibitor [129, 130]. 
Brain penetration of the AEDs phenytoin [130] and phenobarbital [131] increased in rats with 
recurrent seizures after COX-2 inhibition. However, another study found inhibition of COX-2 
with SC-58236 increased adverse effects in a rat seizure model, and advised against the use of 
this inhibitor for adjunctive therapy in drug-resistant epilepsy [132]. The few times COX-1 was 
investigated in relation to ABC transporters, it was found that expression levels are the same 
between parent and P-gp-expressing cells [122], and that inhibition of COX-1 alone did not 
sensitize P-gp-expressing cells to doxorubicin, as was the case with COX-2 inhibition [133]. 
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2 AIMS 
The original goal of this thesis was to develop a PET imaging paradigm to image BCRP 
activity at the BBB. However, the development of a radioligand failed because of the lack of 
a BCRP-specific substrate amendable to radiolabeling. Accordingly, the first goal was 
restricted to a characterization of the actions of the candidate BCRP inhibitor Ko143, as well 
as the P-gp inhibitor tariquidar, which is critical to the in vivo utility of an eventual BCRP 
radiotracer. The second goal remained the same: to explore the roles of efflux transporters 
and neuroinflammation in drug-resistant epilepsy. After the revised overall goals, the specific 
aims of the thesis were: 
1. To assess the specificity of the BCRP inhibitor Ko143 (paper I) 
2. To characterize the inhibitory properties of the P-gp inhibitor tariquidar (paper II) 
3. To determine if sclerosis has an impact on ABC transporter expression in drug-resistant 
epilepsy (paper III) 
4. To measure the cellular expression of the inflammatory proteins COX-1, COX-2, and 
TSPO in drug-resistant epilepsy (paper IV) 
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3 MATERIALS AND METHODS 
3.1 IN VITRO STUDIES 
3.1.1 Chemicals 
3.1.1.1 Radiotracers 
[3H]Ko143 and [3H]tariquidar were synthesized by Moravek Biochemicals (Brea, CA) and 
American Radiolabeled Chemicals (St. Louis, MO), respectively. Both tracers had a 
radiochemical purity > 95% as indicated by high-performance liquid chromatography. 
3.1.1.2 Pharmacological agents 
The P-gp inhibitor (2R)-anti-5-{3-[4-(10,11-dichloromethanodibenzo-suber-5-yl)piperazin-1-
yl]-2-hydroxypropoxy}quinoline trihydrochloride (DCPQ) was provided by Dr. Victor W. 
Pike (National Institute of Mental Health, Bethesda, MD). The remaining chemicals and 
pharmacological agents were purchased commercially. 
3.1.2 Cell lines 
Human or mouse ABC transporter-expressing (resistant) and parental (control) cell lines 
were cultured for use in several in vitro assays (Table 1). The resistant cell lines were 
cultivated via transfection with plasmids containing cDNA of P-gp, BCRP, or MRP1, or 
through the addition of pharmacological agents added to the media (Table 1) [134-140]. 
Parental and resistant HEK-293 cells were provided by Susan Bates (National Cancer 
Institute, Bethesda, MD) and were grown in Eagle’s minimum essential medium (EMEM) 
supplemented with 2 mg/mL G418. LLC-PK1 cells were grown in Medium-199 
supplemented with 500 μg/mL G418, except for the LLC-BCRP cells, which were 
supplemented with 500 μg/mL zeocin. The remaining cell lines were grown in Dulbecco’s 
modified Eagle’s medium (DMEM). Culture medium for all cell lines was supplemented 
with fetal bovine serum (10% for all cells except LLC cells which received 3%), glutamine, 
and antibiotic [141]. All cell lines were grown at 37 °C in 5% CO2. 
3.1.3 Animals 
A cardiac puncture to collect blood was performed using one Sprague-Dawley rat. Animal 
experiments were performed in accordance with the Guide for Care and Use of Laboratory 
Animals [142] and were approved by the National Institute of Mental Health Animal Care 
and Use Committee. 
3.1.4 Cytotoxicity assay 
Cytotoxicity assays were used to measure the interaction between ABC transporters and 
drugs thought to inhibit transporter function. The protocol was followed as described by 
Brimacombe et al. 2009, with the following modifications [143]. Parental and resistant cell 
lines were seeded at a density of 4,000 cells/well. Serial dilutions of the transporter-specific 
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Table 1. Cell lines for papers I and II 
Cell Line Cell Type 
Expressed ABC 
Transporter 
Drug 
Supplementation Paper 
HEK-293 Human embryonic kidney - - 
Paper I 
HEK G2 Human embryonic kidney BCRP - 
HEK B1 Human embryonic kidney P-gp - 
HEK C1 Human embryonic kidney MRP1 4 µM Etoposide 
MCF-7 Human breast cancer - - 
Paper I + II 
FLV10000 Human breast cancer BCRP 10 µg/mL Flavopiridol 
MEF 3.8 Mouse embryonic fibroblast - - 
Paper I + II 
MEF M32 Mouse embryonic fibroblast Mouse BCRP 32 nM Mitoxantrone 
3T3 Mouse embryonic fibroblast - - 
Paper I + II 
C3M Mouse embryonic fibroblast Mouse P-gp 1 µg/mL Colchicine 
KB-3-1 Human adenocarcinoma - - 
Paper II 
KB-8-5-11 Human adenocarcinoma P-gp 250 nM Colchicine 
LLC-PK1 Porcine kidney - - 
Paper II LLC-MDR1 Porcine kidney P-gp - 
LLC-ABCG2 Porcine kidney BCRP -  
 
cytotoxic drugs for P-gp (paclitaxel), BCRP (mitoxantrone), or MRP1 (doxorubicin) were 
made in either EMEM or DMEM. The inhibitors Ko143 and tariquidar were added to the 
wells to assess the ability of these drugs to reverse resistance. Cell viability was measured 
using either the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI), 
or the MTT assay [143]. The outcome measure was the half-maximal inhibitory 
concentration (IC50), which indicates the concentration of cytotoxic drug required to decrease 
cell viability by 50%. 
3.1.5 Flow cytometry 
The ability of ABC transporter inhibitors to increase accumulation of fluorescent substrates 
was measured by flow cytometry. Parental and resistant cells were suspended in either EMEM 
or DMEM at a density of 2.0×105 cells/mL, washed in Iscove’s modified Dulbecco’s medium, 
and resuspended in media containing the fluorescent substrate plus or minus an inhibitor. After 
incubation at 37 °C, cells were washed and resuspended in 0.1% bovine serum albumin in 
phosphate-buffered saline (PBS), and kept on ice until analysis. The samples were read using 
a FACSCalibur, or an LSR II flow cytometer (BD Biosciences, San Jose, CA). 
3.1.6 ATPase assay 
The interaction between ABC transporters and substrates or inhibitors can be measured using 
an ATPase assay. The protocol described in Kannan et al., 2011 was followed [30]. Briefly, 
crude membranes isolated from Hi-five insect cells, which expressed P-gp or BCRP, were 
suspended in ATPase assay buffer. The membranes were incubated with 5 mM ATP, varying 
concentrations of Ko143 or tariquidar, and with or without beryllium fluoride. The hydrolysis 
of ATP was measured using a spectrophotometer at 880 nm [144, 145]. 
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3.1.7 Radioaccumulation assay 
Accumulation of [3H]Ko143 and [3H]tariquidar in parental and resistant cells was used to 
determine the interaction of these radiotracers with the ABC transporters. Cells were seeded 
at a density of 2.5×105 cells/mL in a 24-well plate. Media containing the radiotracer was 
added to the cells, with and without a transporter-specific inhibitor. Six wells did not receive 
radiotracer and were used to account for background noise, while an additional three wells 
were reserved for cell counts to standardize accumulation. After incubation, media was 
removed and cells were washed in PBS. The cells were then trypsinized for 90 minutes, after 
which radioactivity was measured in a liquid scintillation counter. 
3.1.8 High-performance liquid chromatography 
Reverse-phase high-performance liquid chromatography was used to determine the stability 
of the BCRP inhibitor Ko143 in plasma. Whole blood was collected from a rat via cardiac 
puncture, from which the plasma was derived after centrifugation. A saturated solution of 
Ko143 was added to the plasma, with and without the esterase inhibitor NaF. Ko143 was also 
added to dimethyl sulfoxide (DMSO) as a negative control. Samples were then taken at 5, 
10, 15, 30, and 60 minutes, and acetonitrile was used to stop the reaction. The samples were 
injected onto a X-terra Prep C18 column (7.8×300 mm; Waters, Milford, MA), and eluted at 
4 mL/min. 
3.1.9 Transepithelial drug transport assay 
LLC-PK1 cells were used to determine the efflux activity of P-gp and BCRP. Cells were 
seeded at a density of 2×106 cells/well on transwell polycarbonate filters. [3H]tariquidar was 
added to the apical or basolateral side of the monolayer, with and without the addition of a 
P-gp inhibitor (DCPQ) or a BCRP inhibitor (Ko143 or elacridar). At several time points, 
samples were taken from the side opposite to where the [3H]tariquidar was added, and 
radioactivity was measured using a liquid scintillation counter. Fold change in the ratio of 
efflux was calculated by dividing the basolateral to apical transport by the apical to 
basolateral transport. 
3.2 IMMUNOFLUORESCENCE STUDIES 
3.2.1 Human tissue 
We obtained human brain tissue from patients with mesial temporal lobe epilepsy. Patients 
were referred to the Clinical Epilepsy Section, National Institute of Neurological Disorders and 
Stroke, NIH for drug-resistant epilepsy. The study was approved by the NIH Combined 
Neurosciences Institutional Review Board. All patients signed informed consent. An overview 
of patient demographics and pathological diagnosis are provided in Table 2. The tissue was 
formalin fixed, blocked in paraffin, cut into 5 µm sections, and mounted on microscope 
slides. The tissue from each patient was classified by a trained neuropathologist as either 
having mesial temporal sclerosis (MTS) or not (non-MTS) based on guidelines established 
by the International League Against Epilepsy [146].  
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Table 2. Patient information for immunofluorescence studies 
Set n Status Sex 
Average age of 
onset (years) Duration (years) 
A 20 12 MTS 12 Females 13 ± 12.7 20.1 ± 12.4 
B 11 4 MTS 5 Females 11.8 ± 10 19 ± 10.2 
 
3.2.2 Immunofluorescence and scanning 
Protein levels were measured using immunofluorescence techniques, in which the expression 
of primary antibodies bound to specific proteins was visualized using fluorescently 
conjugated secondary antibodies. A BOND-MAX automated stainer (Leica Biosystems, 
Wetzlar, Germany) was used to prepare the slides for staining. The sections were baked at 
60 °C, dewaxed using Bond Dewax Solution (72 °C, Leica Biosystems), and run through a 
heat-induced epitope retrieval step (100 °C, pH 9.0). Outside of the automated stainer, the 
slides were washed in PBS, incubated in 0.03% H2O2 for 30 minutes, and washed again. 
Primary antibodies (Table 3) were diluted in primary antibody buffer (0.3% TX-100, 0.1% 
NaN3, PBS), and were added to the slides for overnight incubation at 4 °C. The following 
day, the slides were washed in Tris-buffered saline (TBS, pH 7.4)-Tween 20 and blocked in 
Tris-NaCl blocking buffer (TNB) (0.1 M Tris-HCl pH 7.5, 0.15 M NaCl, 0.5% blocking 
reagent, Perkin Elmer, Waltham, MA) for 30 minutes. The secondary antibody (Table 3) 
diluted in TNB was then applied to the slides and allowed to incubate for 90 minutes, 
followed by a wash in TBS-Tween 20. For cases in which a horseradish peroxidase (HRP) 
conjugated secondary was used, the slides were labeled with a cyanine dye diluted in 
tyramine signal amplification (TSA) reagent (Perkin Elmer).  
To remove lipofuscin autofluorescence in the tissue, the slides were stained with Sudan Black 
B solution (1% w/v in 70% ethanol, Sigma-Aldrich, St. Louis, MO) for 5 minutes. The slides 
were then washed in 70% ethanol, followed by a PBS wash, and coverslipped using mounting 
medium containing a DAPI counterstain (ProLong Gold Antifade Mountant with DAPI, 
ThermoFisher Scientific, Waltham, MA). Unless otherwise noted, all steps were executed at 
room temperature.  
For multiple staining protocols, efforts were made to use antibodies raised in different 
species. This was not always possible however, and to accommodate multiple antibodies of 
the same species on one slide, the antibodies were developed with HRP-TSA-cyanine 
secondaries. The slides underwent a heat-induced epitope retrieval step as previously 
described, which removed the primary and secondary antibodies and preserved the 
covalently-bound fluorophore-labeled tyramide. This allowed the addition of a second 
antibody without the possibility of cross-reactivity with previous antibodies of the same 
species. Antibodies from Atlas Antibodies (Bromma, Sweden) were validated using multiple 
methods: paired antibodies, in situ hybridization, western blots, and pre-adsorption assays. 
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Table 3. Antibody information for papers III and IV 
Protein 1° antibody Species Dilution  2° antibody Species Dilution Paper 
P-gp Anti-P-gp 
(HPA002199, 
Atlas Antibodies, 
Sweden) 
Rabbit 1:200 HRP-Cy5 Swine anti-
rabbit 
1:200 Paper III 
BCRP Anti-PTGS1 
(HPA054719, 
Atlas Antibodies, 
Sweden) 
Rabbit 1:1200 HRP-Cy5 Swine anti-
rabbit 
1:200 Paper III 
Glut1 Anti-SLC2A1 
(HPA0031345, 
Atlas Antibodies, 
Sweden) 
Rabbit 1:5000 HRP-FITC Swine anti-
rabbit 
1:200 Paper III 
COX-1 Anti-PTGS1 
(HPA002834, 
Atlas Antibodies, 
Sweden) 
Rabbit 1:250 HRP-Cy3 
HRP-Cy5 
Swine anti-
rabbit 
1:200 Paper III + 
IV 
COX-2 Anti-PTGS2 
(HPA001335, 
Atlas Antibodies, 
Sweden) 
Rabbit 1:750 HRP-Cy3 
HRP-Cy5 
Swine anti-
rabbit 
1:200 Paper III + 
IV 
TSPO Anti-PBR  
(ab109497, 
Abcam, U.S.A.) 
Rabbit 1:200 Alexa Fluor 595 
Alexa Fluor 647 
Donkey anti-
rabbit 
1:200 Paper III + 
IV 
GFAP Anti-GFAP  
(ab4674, Abcam, 
U.S.A.) 
Chicken 1:1000 Dylight 488 Donkey anti-
chicken 
1:200 Paper IV 
Iba1 Anti-Iba1  
(ab5076, Abcam, 
U.S.A.) 
Goat 1:100 Cy3 Donkey anti-
goat 
1:200 Paper IV 
NeuN Anti-NeuN, 
Biotinylated 
(ab204681, 
Abcam, U.S.A.) 
Rabbit 1:1000 ABC-Cy3.5 Swine anti-
rabbit 
1:200 Paper IV 
 
Images of the slides were acquired using a fluorescent light microscope (Metasystems, 
Altlußheim, Germany) fitted with at 10x objective. Whole tissue samples on the slides were 
imaged using an automated scanning system, which works by acquiring multiple field of 
view images and subsequently stitching the images together (VSlide Slide Scanning 
Platform, Metasystems). The emission spectra for the fluorescently conjugated secondary 
antibodies are as follows: Hoeschst (420-485 nm), fluorescein (490-530 nm), Cy3 (550-570 
nm), Cy3.5 (580-595 nm), Cy5 (650-670 nm). 
3.2.3 In situ hybridization 
To measure mRNA expression, a RNAscope v. 2.5 protocol (Advanced Cell Diagnostics, 
ACD, Newark, CA) was used in conjunction with the BOND-MAX automated stainer. After 
undergoing the same slide preparation as outlined above, the slides were incubated with an 
ACD proteinase for 15 minutes at 40 °C, followed by H202 for 10 minutes. The slides were 
then incubated with the mRNA probe for two hours at 42 °C. The slides were exposed to a 
series of ACD amplification solutions (ACD AMP 1 – 4) for 15-30 minutes at 42 °C. TSA-
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cyanine secondaries were applied to the slides for 15 minutes at room temperature, which 
bound to the HRP on the ACD AMP 4 reagent. In between each step, the slides were washed 
in Bond Wash Solution (Leica Biosystems). The slides were then stained with Sudan Black, 
coverslipped, and scanned as outlined above. 
3.2.4 Image analysis 
To quantify the expression of proteins as detected by immunofluorescence and in situ 
hybridization, positive pixel intensity was measured using macros in ImageJ (NIH, Bethesda, 
MD) and scripts written in Matlab (Mathworks, Natick, MA). 
3.2.4.1 ImageJ 
From whole pieces of tissues, ≤ 50 500×500 pixel (900 x 900 m) regions of interest (ROIs) 
were randomly generated (Figure 6A). Each ROI contained up to five separate channels: UV, 
fluorescein, Cy3, Cy3.5, and Cy5 (Figure 6B). In some instances, there was bleed through of 
the fluorophore in the fluorescein channel into the Cy3 channel, and from the Cy3.5 channel 
into the Cy3 channel. In these cases, the extent of the bleed through was measured, and 
subtracted from the primary image. This was only performed for non-overlapping cellular 
markers and thus did not affect quantitation. For the inflammation studies in which the COX-
1, COX-2, or TSPO protein was measured in the Cy5 channel, background noise was removed 
by subtracting the median pixel intensity from each image. Because the majority of the pixels 
in any given image in the Cy5 channel were background, the median pixel intensity of the 
image represented the background pixels. The images were then thresholded based on the 
median background intensity plus two standard deviations. 
3.2.4.2 Matlab 
Integrated pixel intensity and average pixel density were used as measures of protein 
concentration (outlined in appendix). To measure protein expression within specific cell types, 
masks of the cells were generated and overlaid onto the image of the protein. Total pixel 
intensity of the protein was then measured within the masks, and average pixel density was 
calculated by taking the total pixel intensity and dividing it by the number of pixels within the 
mask. To generate the masks, the edges of the cells were detected using the Sobel method and 
then smoothed to generate a binary mask. The binary mask was then multiplied by the original 
cell image, which had been thresholded based on the background levels in a similar manner as 
described above. This final mask was then applied to the protein images to measure protein 
expression within the masks (Figure 6C). For proteins measured not within a mask, total pixel 
intensity was measured within the whole ROI, and average pixel density was calculated by 
taking the total pixel intensity and diving it by the total number of pixels within the ROI. 
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Figure 6. Generation of regions of interest (ROIs) and depictions of cell mask outcomes. (A) From each whole 
section of tissue, 50 ROIs were randomly generated. (B) Each ROI contained up to five separate channels. As 
an example, a typical immunofluorescence experiment is shown from paper IV: DAPI in UV, astrocytes (GFAP) 
in fluorescein, microglia (Iba1) in Cy3, neurons (NeuN) in Cy3.5, and COX-1 in Cy5. (C) Masks of the cells (red) 
were then overlaid onto the protein image (COX-1 in this example). Yellow indicates positive overlap between 
the protein and the mask.  
 
3.3 DATA ANALYSIS 
3.3.1 In vitro studies 
For the cytotoxicity assays, the primary outcome measure was IC50, which indicates the 
concentration of cytotoxic drug required to reduce cell viability by 50% compared to 
untreated control cells. Statistical significance was evaluated via Student’s t-test (unpaired, 
two-tailed, α = 0.05). For the flow cytometry experiments, change in fluorescence was 
determined via the geometric mean of fluorescence intensity for a total of 10,00 cells per 
sample. Data were analyzed using Flow Jo software (Tree Star, Ashland, OR). 
ATPase activity was measured by comparing the release of inorganic phosphate after 
incubation with 5 mM ATP before and after the addition of beryllium fluoride. Radioactivity 
was measured using a scintillation counter, adjusted for cell counts and background noise, 
and expressed as fmol/106 cells. Cell counts were obtained from the average of three wells 
not exposed to radiation, while background noise was obtained from the average of three 
wells with nonradioactive media. 
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For the flow cytometry, ATPase, and radioaccumulation assays, statistical significance was 
determined via a one-way analysis of variance, followed by the Bonferroni post-t test (α = 
0.05). Data for all methods are expressed as mean ± SD from three observations, except for 
the high-performance liquid chromatography experiments in which the data was drawn from 
one observation. 
3.3.2 Immunofluorescence studies 
The primary outcome of the immunofluorescence and in situ hybridization studies was the 
percent integrated density of each target protein. This was calculated by dividing the 
integrated density of the protein in the whole ROI by the integrated density of protein within 
the mask. The percent integrated density values from all ROIs (≤ 50) within a piece of tissue 
were then averaged together. This value was then averaged with all data points from that 
experiment. The data are expressed as percent mean integrated density ± SD.  
Linear regression was used to determine the correlation between ABC transporter and 
inflammatory protein expression. Wilcoxon rank sum test was used to determine if there were 
any differences between the MTS and non-MTS groups for each protein. Kruskal-Wallis test 
followed by the Dunn’s multiple comparison test (α = 0.05) was used to determine if there were 
any significant differences in the expression of each inflammatory protein amongst the different 
cell types. When combining tissue batches, logistic regression analysis was used to determine 
if there were any differences between MTS and protein expression, taking into account any 
batch effect.  
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4 RESULTS AND DISCUSSION 
4.1 ASSESSMENT OF ABC TRANSPORTER INHIBITORS 
4.1.1 Ko143 is not selective for BCRP (paper I) 
While Ko143 is often utilized as a BCRP inhibitor in vitro, it was not known if Ko143 was 
specific for BCRP amongst ABC transporters present at the BBB. To this end, we performed 
multiple in vitro experiments with Ko143 to determine how it interacts with the ABC 
transporters. The cells used for these experiments expressed BCRP, P-gp, MRP1, or an 
empty-vector plasmid that acted as the parental cell line (Table 1). The utilization of these 
cells allowed for measurement of the interaction of Ko143 and tariquidar with each 
transporter, without the influence of residual transporter expression. 
To determine if Ko143 was interacting with a transporter, the extent by which Ko143 
inhibited the efflux of transporter-specific substrates was measured. Lower concentrations 
(nanomolar) of Ko143 reversed resistance in cells expressing human or mouse BCRP to the 
cytotoxic drug mitoxantrone by ~1.5-fold. Higher concentrations of Ko143 (micromolar) also 
reversed resistance in cells expressing human or mouse P-gp to paclitaxel by 3-fold and 1.2-
fold, respectively, and human MRP1 to doxorubicin by 3.8-fold.  
In cells expressing human BCRP, all concentrations of Ko143 tested increased accumulation 
of mitoxantrone at least 3.5-fold compared to baseline accumulation (Figure 7). The same 
was found for cells expressing human and mouse P-gp, in which accumulation of rhodamine 
123 increased at all concentrations of Ko143 tested by at least 1.5-fold (Figure 7). The most 
significant increase over baseline was observed in cells expressing human MRP1, in which 
10 – 100 μM of Ko143 increased calcein-AM accumulation by at least 4-fold (Figure 7). 
 
 
Figure 7. Accumulation of transporter-specific fluorescent substrates in cells expressing BCRP, P-gp, MRP1, 
or plasmid control before and after administration of the BCRP inhibitor Ko143. Accumulation is low in 
untreated expressing cells due to efflux of the substrates: mitoxantrone (MTX) for BCRP, rhodamine 123 
(rh123) for P-gp, and calcein AM (CAM) for MRP1. Addition of Ko143 however, reverses resistance in all 
three cells, indicating an interaction between Ko143 and each ABC transporter. This can be compared to the 
uptake of a transporter-specific inhibitor: fumitremorgin C (FTC) for BCRP, cyclosporin A (CSA) for P-gp, 
and MK571 for MRP1.  
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Figure 8. Ko143 is unstable in rat plasma. (A) Ko143 parent compound degrades quickly in rat plasma at room 
temperature. This is reversed with addition of NaF, implying that the parent compound is hydrolyzed by 
esterases in plasma. (B) Chemical structure of the Ko143 parent compound (top) and its primary metabolite, 
Ko143 acid (bottom). (C) Flow cytometry experiment showing that the Ko143 acid has little effect on the 
accumulation of the fluorescent BCRP substrate mitoxantrone (MTX) in BCRP-expressing cells.  
 
Increased binding of [3H]Ko143 was observed in BCRP-expressing cells compared to 
parental cells, which was displaced after addition of either non-radioactive Ko143 or 
fumitremorgin C. There was no difference in the binding in cells expressing either P-gp or 
MRP1 as compared to parental cells. 
Because ABC transporters are ATP-driven efflux pumps, ATPase activity should increase in 
the presence of a substrate, and decrease in the presence of an inhibitor (there is a basal level 
of ATPase activity in the absence of substrate). With increasing concentrations of Ko143, 
ATPase activity decreased in membranes containing BCRP, while it increased in membranes 
containing P-gp. The same concentration of Ko143 (5 μM) elicited a six-fold decrease in 
ATPase activity in the BCRP-expressing cells, and a two-fold increase in ATPase stimulation 
in P-gp-expressing cells. 
Since Ko143 has been used to inhibit BCRP in vivo, it is important to understand the stability 
of Ko143 in plasma, especially given the presence of an ester in the parent compound 
rendering it susceptible to hydrolysis. At room temperature, Ko143 was unstable in rat 
plasma and was undetectable at 60 minutes (Figure 8A). Co-incubation with NaF, an esterase 
inhibitor, inhibited metabolism of Ko143 (Figure 8A). Hydrolysis of the ester group in Ko143 
results in a carboxylic acid functional group. We therefore synthesized the Ko143 acid analog 
(Figure 8B) to determine if the primary metabolic product of Ko143 was also able to inhibit 
BCRP (or whether it resulted in loss of BCRP inhibitory activity). We found that the acid 
had a minimal effect on the accumulation of a fluorescent substrate in cells expressing BCRP 
(Figure 8C), and had no effect on accumulation in cells expressing P-gp, or MRP1. As such, 
the rapid hydrolysis of Ko143 in blood plasma results in a loss of BCRP inhibitory activity. 
The results of this study confirm that Ko143 is a potent inhibitor of both human and mouse 
BCRP. However, it is clear that at higher in vitro concentrations, Ko143 is not specific for 
BCRP since it interacts with P-gp and MRP1. In addition, Ko143 was found to be unstable 
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in rat plasma, although the acid metabolite had no appreciable effect on cellular 
accumulation. Given that Ko143 is not specific for BCRP and is unstable in plasma, Ko143 
should be used with caution for in vitro and in vivo experiments investigating the interaction 
of substrates with BCRP. An imaging probe could facilitate a study to identify the optimal 
dose for specific inhibition of BCRP, but not P-gp, so that Ko143 could be used to study 
BCRP in vivo. 
4.1.2 Tariquidar is an inhibitor of P-gp (paper II) 
Similar to Ko143, tariquidar is often utilized as an ABC transporter inhibitor. Unlike Ko143, 
the interactions of tariquidar with P-gp, BCRP, and MRP1 have been defined by Kannan et 
al. [28]. The authors of this study found tariquidar to be a potent P-gp inhibitor, as well as a 
substrate of BCRP. Recent reports however, have brought into question the nature by which 
tariquidar interacts with P-gp, stating that tariquidar is actually a substrate of P-gp [147]. This 
is significant because this affects whether tariquidar could be used to image P-gp function in 
PET studies. To address this discrepancy, we measured the interactions of tariquidar with 
human and mouse P-gp in a similar manner to those described above. A change in the 
accumulation of transporter-specific substrates after administration of tariquidar was 
attributed to the influence of tariquidar on the transporter. 
Low concentrations (nanomolar) of tariquidar significantly reversed the resistance of cells 
expressing human and mouse P-gp to paclitaxel by 200- and 20-fold, respectively, compared 
to baseline. Similar concentrations reversed resistance to the fluorescent P-gp substrate 
rhodamine 123 in cells expressing human P-gp by 37-fold compared to baseline 
accumulation. In cells expressing mouse P-gp, 1 μM tariquidar increased cellular 
accumulation of rhodamine 123 14-fold. Since tariquidar is inherently fluorescent, we could 
directly measure its intracellular uptake at higher concentrations. In cells expressing P-gp, 
the cellular accumulation of tariquidar was unchanged after addition of a P-gp inhibitor 
(Figure 9A). However, in cells expressing BCRP, cellular accumulation of tariquidar 
increased after inhibition (Figure 9A). Furthermore, 1 μM tariquidar elicited a 50% decrease 
in ATPase activity in both human and mouse P-gp-expressing membranes (Figure 9B). These 
experiments indicate that tariquidar is an inhibitor of both human and mouse P-gp since 
administration of tariquidar leads to increased substrate uptake, and tariquidar itself does not 
accumulate in P-gp-expressing cells. 
ABC transporter inhibitors work by binding to the transporter and thus preventing the 
transporter from pumping substrates out of the cell. Therefore, while substrates are actively 
effluxed across a membrane, inhibitors are not. In line with this, we measured no movement 
of [3H]tariquidar in the basolateral to apical or apical to basolateral direction across 
membranes expressing P-gp (Figure 9C). Addition of a P-gp inhibitor (1 μM) also had no 
effect. On the other hand, significant movement of [3H]tariquidar was measured in the 
basolateral to apical direction across membranes expressing BCRP, consistent with its 
characterization as a BCRP substrate. Transport in this direction was diminished with the 
addition of either BCRP inhibitors. 
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In cellular accumulation studies, [3H]tariquidar binding was 7-fold higher in cells expressing 
human P-gp than in the parental cells (not lower, as would be anticipated for a substrate of 
P-gp) (Figure 9D). Addition of non-radioactive tariquidar displaced the [3H]tariquidar 
binding from the cells (Figure 9D). Similar interactions were observed with [3H]tariquidar 
and mouse P-gp-expressing cells (Figure 9D). As mentioned above, [3H]Ko143 also 
displayed similar binding patterns in cells expressing BCRP. Higher accumulation of the 
tritiated inhibitor is observed because the inhibitor is tightly bound to the transporter. Because 
the transporter is present in the expressing cell lines, but not the parent cell lines, higher 
binding of the inhibitors is observed, which is then displaced by competition from another 
inhibitor. These observations are consistent with another P-gp inhibitor [3H]BIBW22 BS, 
which showed higher binding to P-gp-expressing cells compared with the parent cells [148]. 
The results of this study indicate that tariquidar is an inhibitor of P-gp at in vitro 
concentrations. Any discrepancy in the literature does not appear to be due to species 
differences, since tariquidar inhibited both human and mouse P-gp. This study could not, 
however, examine tariquidar interactions with P-gp at picomolar concentrations, which are 
used in PET imaging with [11C]tariquidar. 
 
 
Figure 9. Tariquidar is not a substrate of P-gp based on multiple in vitro assays. (A) No change in intracellular 
accumulation of tariquidar (which is fluorescent) is observed in P-gp-expressing cells, but can be seen in BCRP-
expressing cells. (B) Both mouse and human P-gp show a decrease in ATPase activity with increasing 
concentrations of tariquidar. If tariquidar were a substrate of P-gp, it would stimulate ATPase activity. (C) 
Transwell assays show no movement in either direction of [3H]tariquidar across P-gp-expressing membranes. 
(D) Accumulation of [3H]tariquidar is higher in P-gp-expressing cells than in control cells. This is due to the 
binding of the inhibitor to the transporter. 
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4.2 ABC TRANSPORTERS AND INFLAMMATION IN EPILEPSY 
4.2.1 ABC transporter expression does not vary with sclerosis (paper III) 
The question as to whether ABC transporter expression is increased at the BBB in drug-
resistant epilepsy, and whether this increase is the cause of the drug resistance, remains 
unanswered. Several groups have used immunohistochemistry methods to answer the former, 
but these studies are plagued by a lack of suitable control tissue given that the type of epilepsy 
tissue obtained is most often fresh surgical tissue. It is often the case that studies will resort 
to using post-mortem tissue, or tissue obtained from other types of brain surgeries, as control 
tissue. 
When the epileptic tissue is 
obtained from the resection 
surgeries, it can be classified based 
on the level of MTS observed upon 
pathological inspection [146]. It 
was previously shown that the non-
MTS tissue was found to be similar 
in pathology (low levels of 
sclerosis and gliosis) compared to 
healthy post-mortem tissue [149]. 
In light of this, we measured ABC 
transporter expression in MTS and 
non-MTS surgical drug-resistant 
epilepsy tissue samples in the hopes 
that the non-MTS tissue could be 
used as a pseudo-control. In 
addition, we compared the 
expression of P-gp and BCRP with 
the expression of the inflammatory 
proteins COX-1, COX-2, and 
TSPO. 
Previous literature shows an 
increase in P-gp expression in 
similar tissue types as compared to 
post-mortem controls and other 
surgical tissue [46-55]. However, a 
strength of the studies described in this thesis is the method used to measure P-gp and BCRP 
expression. Instead of simply counting positively-stained capillaries, an automated method 
of detecting and quantifying expression within capillaries (thus normalizing for capillary 
density) was used (appendix). This allowed for an un-biased quantitative measurement of the 
density of P-gp and BCRP. As a result of the method used to measure ABC transporter 
 
Table 4. Comparison of protein levels between MTS and non-
MTS tissue samples 
     
 Experiment MTS (n) Non-MTS (n) P-value 
 P-gp    
 1 39.5 (12) 36.8 (8) 0.4081 
 2 26.5 (12) 26.1 (8) 0.9344 
 3 40.3 (10) 49.4 (6) 0.0432 
 BCRP    
 1 47.7 (10) 68.1 (7) 0.0512 
 2 68.4 (12) 81.8 (8) 0.1264 
 3 35.6 (12) 50.3 (8) 0.0298 
 4 35.4 (4) 42.2 (7) 0.3932 
 COX-1       
 1 66 (10) 64 (7) 0.8451 
 2 94.0 (12) 70.6 (8) 0.0165 
 COX-2       
 1 123.1 (12) 119.7 (8) 0.4934 
 2 92.5 (12) 90.8 (8) 0.7775 
 TSPO       
 1 92.1 (12) 95.9 (8) 0.0566 
 2 81.7 (10) 84.1 (7) 0.3535 
 3 74.0 (4) 78.3 (7) 0.7922 
 Capillary 
coverage    
 1 1.1 (12) 1.1 (8) 0.9577 
 2 0.80 (12) 1 (8) 0.0919 
 3 1.2 (10) 1.5 (7) 0.1553 
 4 1.2 (10) 1.6 (7) 0.2167 
 5 1.4 (12) 1.9 (8) 0.0303 
 6 1.1 (12) 1.3 (8) 0.1723 
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expression, expression of each protein was measured multiple times across separate 
experiments. Based on immunofluorescence data, there was no difference in P-gp density 
between MTS and non-MTS tissue sets (Table 4). The same was true for BCRP, however 
density in the non-MTS set tended to be higher than in the MTS set (Table 4). No difference 
was observed in capillary density (as determined by the percent coverage of the glut-1 
antibody) between MTS and non-MTS tissue sets (Table 4).  
The expression of P-gp and BCRP was also compared to expression of the inflammatory 
proteins to determine whether ABC transporter expression correlated to inflammation. No 
significant correlation was observed between P-gp and COX-1, COX-2, or TSPO, as well as 
between BCRP and COX-1 or COX-2. A positive correlation was observed however, 
between BCRP density and TSPO density. BCRP density increased in a linear fashion with 
TSPO density (P = 0.0003, r = 0.7213) (Figure 10A). Visual inspection of tissue samples 
with high and low correlations confirm this relationship (Figure 10B). Intensity plots of the 
capillaries in Figure 10B show higher gray values (pixel values) for the high-correlation 
image than for the low-correlation image (Figure 10C). Neither TSPO nor BCRP density was 
correlated with capillary density. This experiment was repeated upon receiving an additional 
set of epilepsy tissue (Table 2, Set B), and the same correlation was observed. There has been 
no mention of a relationship between TSPO and BCRP in the literature, and the meaning 
behind this observation is unclear. Further experimentation is needed to determine whether 
there is a causal relationship between increases in TSPO expression and increases in capillary 
BCRP expression. 
 
 
Figure 10. Increases in BCRP density positively correlated with increases in TSPO density. (A) Relationship 
between BCRP density and TSPO density in tissue set A with MTS (red circles) and non-MTS (black circles) 
tissue samples. (B) Representative images from a tissue sample with a high correlation between BCRP and 
TSPO (top) and a low correlation (bottom). (C) Intensity plots of the BCRP capillary staining from the images 
shown in (B).  
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No change in the expression of P-gp and BCRP was observed between MTS and non-MTS 
drug-resistant epilepsy samples. This study was performed based on the idea that non-MTS 
surgical epilepsy tissue could be used as pseudo-control. Therefore, there are two possible 
explanations for these results: either there are no differences in the expression of P-gp and 
BCRP between epilepsy and control tissue samples, or the expression of these transporters 
is uniform across all types of mesial temporal lobe epilepsy. 
4.2.2 Expression of COX-1, COX-2, and TSPO (paper IV) 
Inflammation is understood to play a role in some types of epilepsy, but its involvement in 
mesial temporal lobe epilepsy is unknown. In animal models of epilepsy, expression of COX-
1 and COX-2 is upregulated compared to healthy animals, lending further proof that 
inflammation has a role in epilepsy [150-157]. The cellular localization of COX-1 and COX-
2 can in some cases determine the function: COX-1 in platelets produces thromboxane A2 
(which enhances coagulation), and COX-2 in vascular endothelium produces prostaglandin 
I2 (which inhibits coagulation) [158]. Little is known about the cellular localization of COX-
1 and COX-2, as well as the inflammation biomarker TSPO, in drug-resistant epilepsy. To 
address this, we measured the expression of COX-1, COX-2, and TSPO in microglia, 
astrocytes, and neurons in drug-resistant epilepsy tissue via immunofluorescence and in situ 
hybridization techniques. The experiments were conducted using both set A and set B of the 
surgical drug-resistant epilepsy tissue (Table 2). 
 
 
Figure 11. Expression patterns of COX-1, COX-2, and TSPO amongst microglia, astrocytes, and neurons. 
COX-1 (top row) is primarily expressed in microglia, with minor expression in astrocytes and neurons. COX-
2 (middle row) is expressed in both microglia and neurons. TSPO (bottom row) is also expressed in microglia 
and neurons. In this image, the protein is shown in red, the cell is shown in green, and the DAPI counterstain is 
shown in blue. White arrows indicate positive overlap between the protein and the cell. Box plots on the right 
show the quantification of staining patterns across all tissue samples.  
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To simplify the data as well as to increase power, the immunofluorescence data from the two 
sets of tissue were pooled and analyzed as a single set. Data is expressed as the percent mean 
integrated density ± SD (see Methods). COX-1 (n = 28) levels were significantly higher in 
microglia (61% ± 11) than in astrocytes (4% ± 2, P < 0.0001) or neurons (8% ± 5, P < 0.0001) 
(Figure 11). Expression in neurons was also significantly higher than in astrocytes (P < 0.05) 
(Figure 11). COX-2 (n = 29) expression was significantly higher in microglia (33% ± 16) and 
neurons (29% ± 12) than in astrocytes (3% ± 2, P < 0.0001) (Figure 11). TSPO (n = 31) 
expression was significantly higher in microglia (50% ± 12) and neurons (32% ± 16) than in 
astrocytes (5% ± 3, P < 0.0001) (Figure 11). In addition, microglia TSPO expression was 
significantly higher than neuronal TSPO expression (P < 0.01) (Figure 11). 
No change was observed in the cellular localization of either protein between MTS and non-
MTS groups. In addition, total expression (within the whole ROI) for COX-1, COX-2, and 
TSPO was also unchanged between MTS and non-MTS groups. No change was observed in 
the density of microglia, astrocytes, and neurons (as determined by the area of the cell mask) 
between groups. In situ hybridization experiments showed higher mRNA expression in 
microglia than in astrocytes for COX-1, COX-2, and TSPO. mRNA expression was not 
measured in neurons because the NeuN antibody was incompatible with the in situ 
hybridization protocol.  
In general, these results coincide with the extant literature: COX-1 is found in microglia and 
COX-2 is expressed in neurons. However, we found a high expression of COX-2 in 
microglia, which has not previously been reported. Only two studies have examined the 
cellular localization of COX-2, and found expression in either astrocytes [159] or neurons 
[159, 160] in surgical drug-resistant epilepsy tissue. One of these studies did find a difference 
in COX-2 expression between MTS and non-MTS tissue samples, however the number of 
tissue samples was low (n = 7) [159]. 
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5 CONCLUSIONS 
The first focus of this thesis was to determine the selectivity and specificity of the BCRP 
inhibitor Ko143, and the P-gp inhibitor tariquidar. We found that although Ko143 is an 
effective inhibitor of BCRP, it also has an effect on the transport activity of P-gp and MRP1. 
In addition, we found Ko143 to be unstable in rat plasma, and that the resultant acid has 
minimal effect on the transporters. We confirmed tariquidar to be a potent inhibitor of both 
mouse and human P-gp. Tariquidar binds to and inhibits P-gp activity, while it is transported 
by BCRP. 
The second focus of this thesis was to measure the expression of P-gp and BCRP, as well as 
the inflammatory proteins COX-1, COX-2, and TSPO in surgical brain tissue samples from 
people with drug-resistant epilepsy. No significant difference in expression of any protein 
was observed between MTS and non-MTS tissue. A positive linear correlation was found 
between BCRP expression and TSPO expression. COX-1 was found to be predominately 
expressed in microglia, while COX-2 and TSPO are expressed in microglia and neurons. 
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6 FUTURE PERSPECTIVES 
Development of a specific substrate radioligand for BCRP. While a PET paradigm exists 
to image P-gp, this is not the case for BCRP. A specific BCRP substrate amendable to 
radiolabeling would allow researchers to measure the activity of BCRP in vivo. This is 
important given the discordant results for BCRP’s activity in diseases like drug-resistant 
epilepsy [56-58]. If BCRP activity is increased in certain diseases, then research can focus 
on how to bypass its efflux mechanisms at the BBB. This is especially crucial given the 
finding (addressed in this thesis) that TSPO and BCRP expression are correlated in brain 
tissue samples from people with drug-resistant epilepsy. PET scans using [11C]PBR28 have 
shown increased TSPO expression in people with drug-resistant epilepsy [106] so it would 
be informative to determine if BCRP activity is also increased in the same patients. A BCRP-
specific substrate would also allow studies into a range of non-BBB pathologies associated 
with BCRP including gout and multidrug-resistant cancer. 
Determine the relationship between BCRP and TSPO. In brain tissue samples from 
people with drug-resistant epilepsy, we found a positive linear correlation between BCRP 
and TSPO expression. This was the only evidence of any relationship between P-gp or BCRP 
and COX-1, COX-2, or TSPO. Further research is needed to determine if increased density 
or activity of the cells expressing TSPO and BCRP expression are linked (co-regulated), and 
the mechanism by which this may occur. In turn, this relationship may provide some insight 
into ABC transporter expression, and ways in which it can be downregulated in the case of 
drug resistance.  
Determine if there are any differences in COX-2 activity between neurons and 
microglia. One finding addressed in this thesis is the expression pattern of COX-2. While 
previous literature has primarily reported neuronal COX-2 in human brain tissue samples 
[159, 160], we found COX-2 to be expressed in both neurons and microglia. Given that the 
product of the COX cascade can be dependent on the type of cell it is expressed in [158], 
further research is warranted to explore if there are any differences in the type of prostanoids 
produced by COX-2 in neurons versus microglia. If so, it would be interesting to know how 
neuronal COX-2 expression differs from microglia COX-2 expression under certain disease 
states.  
Development of radioligands to measure COX-1 and COX-2. Measuring inflammation 
using PET imaging has generally been restricted to TSPO, and while this has been beneficial 
in many ways, TSPO has its drawbacks. The first is that TSPO is expressed in many cell 
types, so that increases in signal cannot solely be attributed to microglia alone [161]. Second, 
astrocytic scarring expresses high levels of TSPO, making TSPO a poor biomarker for acute 
inflammation [162]. Therefore, radioligands specific for inflammatory proteins are needed 
to accurately measure acute microglia-specific inflammatory responses. Work is currently 
underway to implement radioligands specific for COX-1 and COX-2, with the hopes that one 
or both of these radioligands will fulfill these needs.  
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